BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang S, Wang F, Zhang Z. Current advances in the elimination of hepatitis B in China by 2030. Front Med. 2017;11:490-501. [PMID: 29170919 DOI: 10.1007/s11684-017-0598-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Wei L, Lun Y, Zhou X, He S, Gao L, Liu Y, He Z, Li B, Wang C. Novel urokinase-plasminogen activator inhibitor SPINK13 inhibits growth and metastasis of hepatocellular carcinoma in vivo. Pharmacol Res 2019;143:73-85. [PMID: 30862605 DOI: 10.1016/j.phrs.2019.03.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
2 Xiao LL, Wu XX, Chen JJ, Yan D, Shi DY, Huang JR, Xu XW, Li LJ. Progress in hepatitis B virus-related acute-on-chronic liver failure treatment in China: A large, multicenter, retrospective cohort study using a propensity score matching analysis. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00119-3. [PMID: 34303609 DOI: 10.1016/j.hbpd.2021.05.010] [Reference Citation Analysis]
3 Xu S, Zhang W, Wang Q, Cui J, Yan W, Xie H, Ni A. Hepatitis B virus serological screen in a general hospital in Beijing from 2008 to 2018, and challenges to our vaccination policy. Vaccine X 2020;4:100057. [PMID: 32123866 DOI: 10.1016/j.jvacx.2020.100057] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Su QD, Zhang S, Wang F, Liu H, Zhang GM, Zheng H, Qiu F, Sun XJ, Liang XF, Bi SL, Shen LP, Wang FZ. Epidemiological distribution of hepatitis B virus genotypes in 1-29-year-olds in the mainland of China. Vaccine 2020;38:8238-46. [PMID: 33187763 DOI: 10.1016/j.vaccine.2020.09.083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Fang J, Yuan X, Fan L, Du M, Sui W, Ma W, Wang H, Pan AF. Risk factors for incorrect surgical count during surgery: An observational study. Int J Nurs Pract 2021;27:e12942. [PMID: 33837996 DOI: 10.1111/ijn.12942] [Reference Citation Analysis]
6 Ju BJ, Jin M, Tian Y, Zhen X, Kong DX, Wang WL, Yan S. Model for liver hardness using two-dimensional shear wave elastography, durometer, and preoperative biomarkers. World J Gastrointest Surg 2021;13:127-40. [PMID: 33643533 DOI: 10.4240/wjgs.v13.i2.127] [Reference Citation Analysis]
7 Yuan L, Zeng BM, Liu LL, Ren Y, Yang YQ, Chu J, Li Y, Yang FW, He YH, Lin SD. Risk factors for progression to acute-on-chronic liver failure during severe acute exacerbation of chronic hepatitis B virus infection. World J Gastroenterol 2019;25:2327-37. [PMID: 31148904 DOI: 10.3748/wjg.v25.i19.2327] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
8 Wang Y, Tang Z. A novel long-sustaining system of apatinib for long-term inhibition of the proliferation of hepatocellular carcinoma cells. Onco Targets Ther 2018;11:8529-41. [PMID: 30555243 DOI: 10.2147/OTT.S188209] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
9 Jiang Q, Ma Y, Han J, Chu J, Ma X, Shen L, Liu B, Li BA, Hou J, Bi Q. MDM2 Binding Protein Induces the Resistance of Hepatocellular Carcinoma Cells to Molecular Targeting Agents via Enhancing the Transcription Factor Activity of the Pregnane X Receptor. Front Oncol 2021;11:715193. [PMID: 34249768 DOI: 10.3389/fonc.2021.715193] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ellwanger JH, Zambra FMB, Guimarães RL, Chies JAB. MicroRNA-Related Polymorphisms in Infectious Diseases-Tiny Changes With a Huge Impact on Viral Infections and Potential Clinical Applications. Front Immunol 2018;9:1316. [PMID: 29963045 DOI: 10.3389/fimmu.2018.01316] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
11 Zhang Y, Li D, Jiang Q, Cao S, Sun H, Chai Y, Li X, Ren T, Yang R, Feng F, Li BA, Zhao Q. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells. Cell Death Dis 2018;9:743. [PMID: 29970890 DOI: 10.1038/s41419-018-0804-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 54] [Article Influence: 14.0] [Reference Citation Analysis]
12 Xie H, Tian S, Cui L, Yan J, Bai Y, Li X, Wang M, Zhang F, Duan F. Adjuvant trans-arterial chemoembolization after hepatectomy significantly improves the prognosis of low-risk patients with R0-stage hepatocellular carcinoma. Cancer Manag Res 2019;11:4065-73. [PMID: 31118814 DOI: 10.2147/CMAR.S195485] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
13 Zhuo Y, Yang Y, Zhang M, Xu Y, Chen Z, Mu L, Tang X, Zhong Z, Chen J, Zhou L. Single Nucleotide Polymorphisms in IFN-γ Signaling Pathway Associated with Risk of Hepatitis B Virus Infection in Chinese Children. Can J Infect Dis Med Microbiol 2020;2020:8121659. [PMID: 32047575 DOI: 10.1155/2020/8121659] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Deng P, Yang T, Zhang H, Zhou F, Xue C, Fei Y, Gao Y. Prospective clinical trial of hepatitis B vaccination for children with hematological malignancies: a study on the safety and immunogenicity efficacy. Hum Vaccin Immunother 2021;:1-9. [PMID: 34403292 DOI: 10.1080/21645515.2021.1953303] [Reference Citation Analysis]
15 Chai Y, Kan L, Zhao M. Enzymatic extraction optimization, anti-HBV and antioxidant activities of polysaccharides from Viscum coloratum (Kom.) Nakai. International Journal of Biological Macromolecules 2019;134:588-94. [DOI: 10.1016/j.ijbiomac.2019.04.173] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 7.5] [Reference Citation Analysis]
16 Du Y, Du B, Fang X, Shu M, Zhang Y, Chung H, Sun Y, Teng J, Visalath P, Qiu H, Cai W. ALT Flare Predicts Hepatocellular Carcinoma Among Antiviral Treated Patients With Chronic Hepatitis B: A Cross-Country Cohort Study. Front Oncol 2020;10:615203. [PMID: 33552989 DOI: 10.3389/fonc.2020.615203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Sun H, Feng F, Xie H, Li X, Jiang Q, Chai Y, Wang Z, Yang R, Li R, Hou J. Quantitative examination of the inhibitory activation of molecular targeting agents in hepatocellular carcinoma patient-derived cell invasion via a novel in vivo tumor model. Animal Model Exp Med 2019;2:259-68. [PMID: 31942558 DOI: 10.1002/ame2.12085] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
18 Lu C, Fu W, Zhou R, Hu W. Network pharmacology-based study on the mechanism of Yiganling capsule in hepatitis B treatment. BMC Complement Med Ther 2020;20:37. [PMID: 32024508 DOI: 10.1186/s12906-020-2815-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Yin F, Feng F, Wang L, Wang X, Li Z, Cao Y. SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity. Cell Death Dis 2019;10:672. [PMID: 31511501 DOI: 10.1038/s41419-019-1884-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 15.0] [Reference Citation Analysis]
20 Shi JF, Cao M, Wang Y, Bai FZ, Lei L, Peng J, Feletto E, Canfell K, Qu C, Chen W. Is it possible to halve the incidence of liver cancer in China by 2050? Int J Cancer 2021;148:1051-65. [PMID: 32997794 DOI: 10.1002/ijc.33313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Fan X, Xu W, Gao W, Xiao H, Wu G. Opsonization of multiple drug resistant (MDR)-bacteria by antimicrobial peptide fused hepatitis B virus surface antigen (HBsAg) in vaccinated individuals. Biochem Biophys Res Commun 2021;534:193-8. [PMID: 33280820 DOI: 10.1016/j.bbrc.2020.11.113] [Reference Citation Analysis]
22 Cui Y, Cui XD, Xu M, Fang M, Cai MJ. Serum apolipoprotein C3 levels are negatively associated with hepatitis B virus DNA in HBeAg-negative chronic hepatitis B patients. Lipids Health Dis 2019;18:138. [PMID: 31186008 DOI: 10.1186/s12944-019-1084-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Yang B, Wang C, Xie H, Wang Y, Huang J, Rong Y, Zhang H, Kong H, Yang Y, Lu Y. MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents. Cell Death Dis 2019;10:784. [PMID: 31611551 DOI: 10.1038/s41419-019-2023-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 12.5] [Reference Citation Analysis]
24 Wang Y, Pei L, Yue Z, Jia M, Wang H, Cao LL. The Potential of Serum Exosomal hsa_circ_0028861 as the Novel Diagnostic Biomarker of HBV-Derived Hepatocellular Cancer. Front Genet 2021;12:703205. [PMID: 34367259 DOI: 10.3389/fgene.2021.703205] [Reference Citation Analysis]
25 Shao QP, Wei C, Yang J, Zhang WZ. miR-3609 Decelerates the Clearance of Sorafenib in Hepatocellular Carcinoma Cells by Targeting EPAS-1 and Reducing the Activation of the Pregnane X Receptor Pathway. Onco Targets Ther 2020;13:7213-27. [PMID: 32801751 DOI: 10.2147/OTT.S246471] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
26 Shao Z, Li Y, Dai W, Jia H, Zhang Y, Jiang Q, Chai Y, Li X, Sun H, Yang R, Cao Y, Feng F, Guo Y. ETS-1 induces Sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR. Pharmacol Res 2018;135:188-200. [PMID: 30114438 DOI: 10.1016/j.phrs.2018.08.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 44] [Article Influence: 10.0] [Reference Citation Analysis]
27 Zeng Y, Luo M, Lin J, He H, Deng X, Xie S, Fang Y. Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobulin treatment: a case study in Zhejiang Province, East China. Hum Vaccin Immunother 2020;16:955-64. [PMID: 31769718 DOI: 10.1080/21645515.2019.1688031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Ren X, Zhang L, Xia S, Zhou J, Lin Y, Zhijie C, Li R, Zhan W. Diagnostic Performance of Shear Wave Elastography in the Noninvasive Evaluation of Liver Inflammation of Chronic Hepatitis B Patients. Ultrasound Q 2021;37:111-7. [PMID: 34009924 DOI: 10.1097/RUQ.0000000000000522] [Reference Citation Analysis]
29 Jiang S, Jiang W, Xu Y, Wang X, Mu Y, Liu P. Serum miR-21 and miR-26a Levels Negatively Correlate with Severity of Cirrhosis in Patients with Chronic Hepatitis B. Microrna 2019;8:86-92. [PMID: 30147020 DOI: 10.2174/2211536607666180821162850] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Gao X, Chen H, Huang X, Li H, Liu Z, Bo X. ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance. Onco Targets Ther 2019;12:1629-40. [PMID: 30881018 DOI: 10.2147/OTT.S196713] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
31 Xu F, Zeng Z, Yan B, Fu Y, Sun Y, Yang G, Tu L, Watanabe S, Jabbour SK, Bravaccini S, Fanini F, Zhou J, Shen Y. Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study. Transl Lung Cancer Res 2021;10:1819-28. [PMID: 34012795 DOI: 10.21037/tlcr-21-79] [Reference Citation Analysis]
32 Hou FJ, Guo LX, Zheng KY, Song JN, Wang Q, Zheng YG. Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells. Onco Targets Ther 2019;12:6685-97. [PMID: 31695406 DOI: 10.2147/OTT.S215103] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
33 Xiao LL, Xu XW, Huang KZ, Zhao YL, Zhang LJ, Li LJ. Artificial Liver Support System Improves Short-Term Outcomes of Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Propensity Score Analysis. Biomed Res Int 2019;2019:3757149. [PMID: 31871940 DOI: 10.1155/2019/3757149] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]